Denmark· DK-28106703821
Ronapreve
A casirivimab and imdevimab product containing casirivimab, imdevimab, registered in Denmark by Roche Registration GmbH. The same ATC class is registered in 5 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Casirivimab and imdevimab is registered in 5 of 19 countries.
Countries holding a registration under ATC J06BD07 (casirivimab and imdevimab), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 4 of them publish a price we can compare per daily dose
Casirivimab and imdevimab · ATC J06BD07
5 / 19 countries
- Belgiumprice
- Denmark
- Finlandprice
- Polandprice
- Spainprice
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Casirivimab, Imdevimab
- Manufacturer
- Roche Registration GmbH
- Country
- Denmark (DK)
- ATC code
- J06BD07
- ATC class
- Casirivimab and imdevimab
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 2, 2026
Packs & prices · 1
- dk_varenummer28106703821
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under J06BD07
Casirivimab and imdevimab, as other registers publish it.
- PolandRonapreveRoche Registration GmbH
- FinlandRonapreveRoche Registration GmbH
- FinlandRonapreveRoche Registration GmbH
- DenmarkRonapreveRoche Registration GmbH
- BelgiumRonapreve 120 mg/ml - 120 mg/mlRoche Registration
- SpainRONAPREVE 120 MG/ML + 120 MG/ML SOLUCIÓN INYECTABLE Y PARA PERFUSIÓNRoche Registration Gmbh
- BelgiumRonapreve 300 mg - 300 mgRoche Registration
- SpainRONAPREVE 300 MG + 300 MG SOLUCIÓN INYECTABLE Y PARA PERFUSIÓNRoche Registration Gmbh
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5f49d484-3df9-422f-a1aa-1b2104ce27e5 GET /v1/drugs/5f49d484-3df9-422f-a1aa-1b2104ce27e5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "injektions-/infusionsvæske, opløsning",
"source": "dkma",
"strength": "300 mg + 300 mg",
"auth_role": "MOD",
"dk_drugid": "28106703821",
"substance": "Casirivimab, Imdevimab",
"auth_procedure": "Central",
"in_medicinpriser": false,
"registration_date_serial": "44512"
}See everything about casirivimab and imdevimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.